Q32 Financial Statements From 2010 to 2026

QTTB Stock   4.23  0.25  6.28%   
Q32 Bio's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Q32 Bio's valuation are provided below:
Gross Profit
-26.4 M
Market Capitalization
49 M
Revenue
-14.7 M
Earnings Share
(3.40)
Revenue Per Share
(1.10)
We have found one hundred twenty available fundamental measures for Q32 Bio, which can be analyzed and compared to other ratios and to its peers in the sector. All investors should make sure to check out all of Q32 Bio latest market performance against the performance between 2010 and 2026 to make sure the company can sustain itself this quarter and beyond. As of February 4, 2026, Market Cap is expected to decline to about 45.8 M. The current year's Enterprise Value is expected to grow to about (18.7 M)

Q32 Bio Total Revenue

0.0

Check Q32 Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Q32 Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 532 K, Other Operating Expenses of 77.4 M or Research Development of 57.9 M, as well as many indicators such as Dividend Yield of 0.0, Ptb Ratio of 14.34 or Book Value Per Share of 0.51. Q32 financial statements analysis is a perfect complement when working with Q32 Bio Valuation or Volatility modules.
  
Build AI portfolio with Q32 Stock
Check out the analysis of Q32 Bio Correlation against competitors.
For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.

Q32 Bio Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets124.3 M83.1 M99.5 M
Slightly volatile
Other Current Liabilities8.8 M11.2 M7.3 M
Slightly volatile
Total Current Liabilities21.8 M18.9 M15.1 M
Slightly volatile
Property Plant And Equipment Net6.1 M6.4 M11.3 M
Slightly volatile
Accounts Payable3.3 M2.7 M2.8 M
Pretty Stable
Cash76.8 M89.7 M50.8 M
Slightly volatile
Non Current Assets Total11.4 M12 M13.8 M
Slightly volatile
Other Assets0.80.90.9824
Slightly volatile
Cash And Short Term Investments101.2 M70.2 M81.1 M
Slightly volatile
Net Receivables687 K638.2 K458.9 K
Slightly volatile
Common Stock Shares Outstanding14.7 M14 M4.3 M
Slightly volatile
Liabilities And Stockholders Equity124.3 M83.1 M99.5 M
Slightly volatile
Non Current Liabilities Total73.5 M80.7 M44.6 M
Slightly volatile
Other Current Assets6.8 M3.9 M4.1 M
Slightly volatile
Other Stockholder Equity420.1 M276.6 M243.3 M
Slightly volatile
Total Liabilities95.3 M99.7 M59.7 M
Slightly volatile
Total Current Assets106.7 M73.7 M85.5 M
Slightly volatile
Common StockK2.3 K2.1 K
Slightly volatile
Current Deferred Revenue17.5 M16.7 M6.8 M
Slightly volatile
Short Term Investments37.1 M39 M82.9 M
Pretty Stable
Inventory2.1 MM642 K
Slightly volatile
Short and Long Term Debt Total33.8 M21.7 M21.4 M
Slightly volatile
Short Term Debt4.1 M4.3 M4.4 M
Pretty Stable
Long Term Debt17.3 M11 M8.6 M
Slightly volatile
Property Plant And Equipment Gross7.6 M9.8 M2.8 M
Slightly volatile
Capital Stock1.4 K2.3 K1.2 K
Slightly volatile
Non Current Liabilities Other40.6 M63.2 M16.3 M
Slightly volatile
Short and Long Term Debt2.6 M2.8 M25.3 M
Slightly volatile

Q32 Bio Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization532 K560 K1.8 M
Pretty Stable
Other Operating Expenses77.4 M76 M49.8 M
Slightly volatile
Research Development57.9 M55.4 M36.5 M
Slightly volatile
Cost Of Revenue416.4 K438.3 K2.7 M
Pretty Stable
Total Operating Expenses74 M75.5 M47.9 M
Slightly volatile
Tax Provision18 K18.9 K411.9 K
Slightly volatile
Selling General Administrative12.3 M20.7 M8.9 M
Slightly volatile
Reconciled Depreciation385.8 K560 K168.6 K
Slightly volatile
Selling And Marketing Expenses16.6 M18.7 M20.4 M
Slightly volatile
Net Interest Income2.2 M2.5 M2.8 M
Slightly volatile
Interest Income3.1 M3.5 M3.8 M
Slightly volatile
Interest Expense240 K270 K294.7 K
Slightly volatile

Q32 Bio Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow60.2 M36 M42.3 M
Slightly volatile
Depreciation532 K560 K1.8 M
Pretty Stable
Capital Expenditures64.1 K67.5 K4.2 M
Very volatile
Total Cash From Financing Activities58.3 M85.6 M47.2 M
Slightly volatile
End Period Cash Flow77.6 M90.4 M51.2 M
Slightly volatile
Stock Based Compensation5.3 MM1.6 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables7.3 M8.2 MM
Slightly volatile
Capex To Depreciation0.170.185.3904
Slightly volatile
Payables Turnover0.140.151.1213
Pretty Stable
Cash Per Share6.987.3530.9799
Pretty Stable
Days Payables OutstandingKK1.2 K
Pretty Stable
Current Ratio9.385.726.0672
Slightly volatile
Capex Per Share0.00670.00712.1021
Very volatile
Interest Debt Per Share1.721.816.4304
Very volatile
Debt To Assets0.350.180.1939
Slightly volatile
Days Of Payables OutstandingKK1.2 K
Pretty Stable
Ebt Per Ebit0.760.650.8724
Pretty Stable
Quick Ratio9.385.726.0654
Slightly volatile
Net Income Per E B T1.11.151.0162
Slightly volatile
Cash Ratio4.55.453.3831
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.231.151.1667
Pretty Stable
Debt Ratio0.350.180.1939
Slightly volatile
Gross Profit Margin0.580.650.7068
Slightly volatile

Q32 Bio Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap45.8 M48.3 M472 M
Slightly volatile

Q32 Fundamental Market Drivers

About Q32 Bio Financial Statements

Q32 Bio stakeholders use historical fundamental indicators, such as Q32 Bio's revenue or net income, to determine how well the company is positioned to perform in the future. Although Q32 Bio investors may analyze each financial statement separately, they are all interrelated. For example, changes in Q32 Bio's assets and liabilities are reflected in the revenues and expenses on Q32 Bio's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Q32 Bio. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue16.7 M17.5 M
Cost Of Revenue438.3 K416.4 K
Stock Based Compensation To Revenue(0.25)(0.23)
Sales General And Administrative To Revenue(1.71)(1.62)
Research And Ddevelopement To Revenue(5.49)(5.21)
Revenue Per Share(2.38)(2.26)
Ebit Per Revenue 6.53  6.86 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Q32 Bio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Q32 Bio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Q32 Bio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Q32 Bio Stock:
Check out the analysis of Q32 Bio Correlation against competitors.
For information on how to trade Q32 Stock refer to our How to Trade Q32 Stock guide.
You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Q32 Bio. Anticipated expansion of Q32 directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Q32 Bio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share
(3.40)
Revenue Per Share
(1.10)
Return On Assets
(0.34)
Return On Equity
(4.92)
The market value of Q32 Bio is measured differently than its book value, which is the value of Q32 that is recorded on the company's balance sheet. Investors also form their own opinion of Q32 Bio's value that differs from its market value or its book value, called intrinsic value, which is Q32 Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Q32 Bio's market value can be influenced by many factors that don't directly affect Q32 Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Q32 Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Q32 Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Q32 Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.